pxlence is hiring a project-manager to develop and market products for precision oncology! If you fit the profile and wish to work in an young and dynamic company focusing on cancer detection methods in liquid biopsies, feel free to submit your resume though our contact page.
We've updated our website to make the available information more easily accessible and streamline the ordering process. If you find any bugs or have comments on how to further improve our site, please let us know!
pxlence has a stand at the Belgian Society for Human Genetics in Ghent, February 16, 2018. Pay us a visit and try one of our tasty sweets!
pxlence will be present at the European Society for Human Genetics in Barcelona, May 21-24, 2016. Contact us if you would like to setup a meeting to discuss your targeted resequencing needs.
pxlence co-founder and CEO, Frauke Coppieters, presents a poster at the American Society for Human Genetics in Baltimore, October 6-10, 2015.
We are proud to announce of our second catalogue containing assays ranging 125-275 bp in length, covering almost 99% of the human exome. Discover them here.
pxlence presents poster at the 15th Belgian Society for Human Genetics meeting (Charleroi, Belgium)
CTO Steve Lefever presents at the qPCR and NGS 2015 Symposium (Freising, Germany) "Targeted resequencing and variant validation using pxlence PCR assays
pxlence participated in the 7th Universal Biotech Innovation Prize.
Come and meet us at Knowledge for Growth, Europe's leading regional biotech convention (Ghent, Belgium)
Our market survey about variant confirmation and targeted resequencing is closed. Thank you all for participating in such large numbers! From all participants, 5 people winning 50 free targeted resequencing assays each have been randomly selected and contacted. Congratulations!